FDA tells Compass Therapeutics to run survival trial before BLA for tovecimigSep 22Clinical readoutCompass Therapeutics
Compass Therapeutics awaits FDA input on tovecimig biliary cancer dataAug 6Quarterly updateCompass Therapeutics
Compass Therapeutics posts Phase 2 results for CTX-009 in metastatic colorectal cancer trialJul 28Trial updateCompass TherapeuticsCTX-009
Compass Therapeutics registers Phase 2 study of CTX-471 in NCAM-positive neuroendocrine tumorsJul 6Trial updateCompass TherapeuticsCTX-471
Sign in